Research Report
11 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Bate Scecile
Scoop.it!

2022 Systemic Lupus Erythematosus and Lupus Nephritis Market Forecasts

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 is a market research report available at US $9995 for a Single User PDF License from RnR Market Research Reports Library.
Bate Scecile's insight:

The Report “PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis – Global Drug Forecast and Market Analysis to 2022″ by GlobalData is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis – Global Drug Forecast and Market Analysis to 2022″ in subject line and your contact details to purchase this report or get your questions answered.

The lupus therapeutics market is dominated by generics and GlaxoSmithKline’s Benlysta is the only drug that has gained marketing approval for SLE in more than 50 years. Following Benlysta’s launch, patients’ uptake has remained low, but due to its associated high price-tag Benlysta has managed to grow the lupus market in terms of value and is currently the second top-selling drug in this market, having generated approximately $107m in 2012 in the seven major markets. The top-selling drug in lupus in terms of value is Roche’s off-label Rituxan, which Researcher estimates generated approximately $170m in 2012 in the seven major markets. There is high R&D activity for the development of new therapies for lupus and six promising biological therapies can potentially enter the SLE and LN market from 2017 to 2022. Anthera Pharmaceuticals, Eli Lilly and Merck Serono are developing anti-BLyS therapies. UCB’s epratuzumab is an anti-CD22, ImmuPharma’s Lupuzor is a CD4 T-cell modulator and Bristol-Myers Squibb’s Orencia is an anti-CD80/CD86 therapy. The introduction of new biologic drugs will shape the future competitive landscape and drive growth in the SLE and LN markets.

Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=120530 .

Key Questions Answered

What was the impact of Benlysta on the lupus therapeutics market following its approval in 2011 and what is its future outlook within this market?What do physicians think about Rituxan following its unsuccessful Phase III trials in LN, and how will it be used off-label in lupus during the forecast period?What is the significance of late-phase pipeline products and how will their launch shape the future treatment landscape in SLE and LN?What are the unmet needs within the SLE and LN markets?What are the remaining opportunities within the SLE and LN markets?

Complete report is available @ http://www.rnrmarketresearch.com/pharmapoint-systemic-lupus-erythematosus-and-lupus-nephritis-global-drug-forecast-and-market-analysis-to-2022-market-report.html . Read more on “PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis – Global Drug Forecast and Market Analysis to 2022” report below.

Key Findings

The main drivers of growth for the SLE and LN markets include the increasing uptake of biologics, the launch of Benlysta in Japan, the launch of new biologic drugs during the second half of the forecast period and the increasing number of prevalent cases of SLE and LN.R&D strategies include the development of me-too and first-in-class therapies, partnerships and acquisitions, and the development of products for LN.The lupus therapeutics market is characterized by significant unmet needs. The most pressing unmet need is the development of new therapies that will offer potent clinical benefits, have a positive safety profile and increase the available treatment options for patients.With high R&D activity in the lupus therapeutics market, physicians are looking forward to pipeline products becoming available, which will enable them to improve patients’ treatment.

Scope

Overview of SLE and LN, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.Annualized SLE and LN therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the SLE and LN therapeutics markets.Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of mid-stage pipeline drugs.Analysis of the current and future market competition in the global SLE and LN therapeutics markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.Additionally a list of acquisition targets included in the pipeline product company list.Develop business strategies by understanding the trends shaping and driving the global SLE and LN therapeutics markets.Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global SLE and LN therapeutics markets in the future.Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.Track drug sales in the global SLE and LN therapeutics markets from 2012-2022.Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

For further information on “PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis – Global Drug Forecast and Market Analysis to 2022” report OR for any other business research / market intelligence need on the ‘Autoimmune Drugs’ market (http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/autoimmune-drugs . ), contact sales@rnrmarketresearch.com / Call +1 888 391 5441.

 

About Us:

RnRMarketResearch.com is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest.

 

You can also reach us @

http://rnrmarketresearch.blogspot.in/

http://www.rnrmarketresearch.com/blog/

http://www.facebook.com/pages/RnR-Market-Research/413488545356345

https://plus.google.com/u/0/104156468549256253075/

https://twitter.com/#!/RnRMR

http://www.dailymotion.com/rnrmarketresearch

http://www.youtube.com/user/rnrmarketresearch

http://www.slideshare.net/rnrmarketresearch3/

more...
No comment yet.
Scooped by Bate Scecile
Scoop.it!

Wrinkles Industry key Drugs Clinical Review

Wrinkles Industry key Drugs Clinical Review | Research Report | Scoop.it
Wrinkles Global Clinical Trials Review, H1, 2014 is a market research report available at US $2500 for a Single User PDF License from RnR Market Research Reports Library.
Bate Scecile's insight:

The Report “Wrinkles Global Clinical Trials Review, H1, 2014″ by GlobalData is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “Wrinkles Global Clinical Trials Review, H1, 2014″ in subject line and your contact details to purchase this report or get your questions answered.

“Wrinkles Global Clinical Trials Review, H1, 2014″ provides data on the Wrinkles clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Wrinkles. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Wrinkles.

Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=149035 .

Scope

Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nationsClinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor typeListings of discontinued trials (suspended, withdrawn and terminated)

Complete report is available @ http://www.rnrmarketresearch.com/wrinkles-global-clinical-trials-review-h1-2014-market-report.html .Read more on “Wrinkles Global Clinical Trials Review, H1, 2014” report below.

Reasons to buy

Understand the dynamics of a particular indication in a condensed mannerAbridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many moreObtain discontinued trial listing for trials across the globeEspy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

 

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Wrinkles 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Wrinkles to Dermatology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Wrinkles to Dermatology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Wrinkles 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Wrinkles Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Wrinkles 31
Apr 17, 2012: Fibrocell Science Announces Publication Of LAVIV Pivotal Trial Data In Dermatologic Surgery 31
Nov 07, 2011: Studies Show LAVIV Effectively Improves Appearance Of Smile Line Wrinkles 31
Oct 22, 2010: Revance Presents Clinical Trial Results Of RT001 Topical Gel At Annual Meeting Of American Society Of Dermatologic Surgery 32
Aug 31, 2010: Oxygen Biotherapeutics Reports DERMACYTE Oxygen Concentrate Improved Appearance Of Fine Lines And Perception Of Skin Appearance 33
May 13, 2010: Fibrocell Initiates Histology Study Of Azficel-T 34
Clinical Trial Profiles 35
Clinical Trial Overview of Top Companies 35
Allergan, Inc. 35
Clinical Trial Overview of Allergan, Inc. 35
Revance Therapeutics, Inc. 36
Clinical Trial Overview of Revance Therapeutics, Inc. 36
Merz Pharma GmbH & Co. KgaA 37
Clinical Trial Overview of Merz Pharma GmbH & Co. KgaA 37
Galderma S.A. 38
Clinical Trial Overview of Galderma S.A. 38
Fibrocell Science, Inc. 39
Clinical Trial Overview of Fibrocell Science, Inc. 39
Anterios Inc. 40
Clinical Trial Overview of Anterios Inc. 40
Kasiak Research Pvt. Ltd. 41
Clinical Trial Overview of Kasiak Research Pvt. Ltd. 41
Ipsen S.A. 42
Clinical Trial Overview of Ipsen S.A. 42
DeNova Research 43
Clinical Trial Overview of DeNova Research 43
Allergan S.A. 44
Clinical Trial Overview of Allergan S.A. 44
Clinical Trial Overview of Top Institutes / Government 45
Brazilian Center for Studies in Dermatology 45
Clinical Trial Overview of Brazilian Center for Studies in Dermatology 45
Northwestern University 46
Clinical Trial Overview of Northwestern University 46
Dermatologikum Hamburg 47
Clinical Trial Overview of Dermatologikum Hamburg 47
Johns Hopkins University 48
Clinical Trial Overview of Johns Hopkins University 48
Nagoya University 49
Clinical Trial Overview of Nagoya University 49
Kyunghee University Medical Center 50
Clinical Trial Overview of Kyunghee University Medical Center 50
Mahidol University 51
Clinical Trial Overview of Mahidol University 51
The New York Eye and Ear Infirmary 52
Clinical Trial Overview of The New York Eye and Ear Infirmary 52
Laserklinik Karlsruhe 53
Clinical Trial Overview of Laserklinik Karlsruhe 53
Five Key Clinical Profiles 54
Appendix 99
Abbreviations 99
Definitions 99
Research Methodology 100
Secondary Research 100
About GlobalData 101
Contact Us 101
Disclaimer 101
Source 102

 

For further information on “Wrinkles Global Clinical Trials Review, H1, 2014” report OR for any other business research / market intelligence need on the ‘Clinical Trial’ market (http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/clinical-trial . ), contact sales@rnrmarketresearch.com / Call +1 888 391 5441.

 

About Us:

RnRMarketResearch.com is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest.

 

You can also reach us @

http://rnrmarketresearch.blogspot.in/

http://www.rnrmarketresearch.com/blog/

http://www.facebook.com/pages/RnR-Market-Research/413488545356345

https://plus.google.com/u/0/104156468549256253075/

https://twitter.com/#!/RnRMR

http://www.dailymotion.com/rnrmarketresearch

http://www.youtube.com/user/rnrmarketresearch

http://www.slideshare.net/rnrmarketresearch3/

 

more...
No comment yet.
Scooped by Bate Scecile
Scoop.it!

2017 Forecasts for Janitorial Equipment and Supplies Marke

2017 Forecasts for Janitorial Equipment and Supplies Marke | Research Report | Scoop.it
Janitorial Equipment & Supplies to 2017 is a market research report available at US $5100 for a Single User PDF License from RnR Market Research Reports Library.
Bate Scecile's insight:

The Report “Janitorial Equipment & Supplies to 2017″ by Freedonia Groupis now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “Janitorial Equipment & Supplies to 2017″ in subject line and your contact details to purchase this report or get your questions answered.

 

This study analyzes the US janitorial equipment and supply industry. It presents historical demand data (2002, 2007, 2012) and forecasts for 2017 and 2022 by product (e.g., manual cleaning products, bags and containers, automated floor cleaning equipment), market (e.g., office buildings, institutional buildings, commercial buildings, industrial buildings, residential buildings), purchaser (in-house cleaner, contract cleaner), and US region. The study also considers market environment factors, evaluates company market share, and profiles industry competitors.

 

US demand to rise 1.7% annually through 2017

Demand for janitorial equipment and supplies in the US is forecast to advance 1.7 percent per year through 2017 to $7.2 billion. This rate is an improvement from the more sluggish gains of the 2007-2012 period. Sales of many of these products declined from 2007 to 2009 due to the recession and its subsequent effect on business activity levels. However, many businesses began purchasing new equipment between 2010 and 2012 as the economy improved, helping sales of most products return to pre-recession levels.

 

Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=118093 .

 

Higher-end products to support value gains

Through 2017, sales of janitorial equipment and supplies will be driven by continuing economic recovery and the corresponding return to higher levels of demand for cleaning activity, as well as expansion in the number of nonresidential establishments and floor space. Rising focus on sustainable practices will drive demand for higher value environmentally friendly products that use less water and cleaning solution than comparable items. Ergonomic products will also continue to support value growth. However, overall gains will be limited to an extent by the reluctance of companies to reintroduce cleaning and maintenance costs that they cut during the recession.

 

Manual cleaning products to be fastest growing types

Manual cleaning products are forecast to experience the fastest growth through 2017, driven by a more delayed recovery from the effects of the recession, as well as ongoing product development. For instance, sales of products such as wipes, cloths, and flat and wet mops will benefit from the continuing adoption of higher value microfiber, which requires minimal use of chemicals and lasts longer than standard products.

 

Complete report is available @ http://www.rnrmarketresearch.com/janitorial-equipment-supplies-to-2017-market-report.html . Read more on “Janitorial Equipment & Supplies to 2017” report below.

 

Institutional market to post the fastest gains

The institutional building market will post the fastest gains through 2017. This sector will exhibit the most rapid growth in floor space due to an increase in the number of health care and related establishments. In addition, these locations have a particular interest in higher value products that can reduce the risk of cross contamination and maintain indoor air quality, such as disposable microfiber flat mops, no-touch cleaning equipment, and automated cleaning products with advanced particle filtration features. The residential market will also exhibit above average gains as homeowners return to more frequent use of contract cleaners who employ these commercial grade products.

 

Contract cleaners to outpace in-house staff

Businesses will continue to turn to contract cleaners to reduce overhead costs associated with building maintenance. Purchases of janitorial equipment and supplies by contract cleaners are expected to outpace those of in-house staff in every market except for the industrial sector. This is due in part to the often unique and exacting cleaning needs in certain types of manufacturing environments, such as pharmaceutical or food processing, that may be better suited to an in-house staff familiar with the facilities needs.

 

Company Profiles

Profiles 30 industry competitors such as Electrolux, Heritage Bag, Alfred Karcher, Katy Industries, Newell Rubbermaid, Nilfisk-Advance, Techtronic Industries, Tennant, 3M and Weiler

 

For further information on “Janitorial Equipment & Supplies to 2017” report OR for any other business research / market intelligence need on the ‘Household Cleaning’ market (http://www.rnrmarketresearch.com/reports/consumer-goods/house-home-care/household-cleaning .), contact sales@rnrmarketresearch.com / Call +1 888 391 5441.

 

About Us:

RnRMarketResearch.com is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest.

 

You can also reach us @

http://rnrmarketresearch.blogspot.in/

http://www.rnrmarketresearch.com/blog/

http://www.facebook.com/pages/RnR-Market-Research/413488545356345

https://plus.google.com/u/0/104156468549256253075/

https://twitter.com/#!/RnRMR

http://www.dailymotion.com/rnrmarketresearch

http://www.youtube.com/user/rnrmarketresearch

http://www.slideshare.net/rnrmarketresearch3/

more...
No comment yet.
Scooped by Bate Scecile
Scoop.it!

Postmenopausal Vaginal Atrophy Market Forecast to 2022

Postmenopausal Vaginal Atrophy Market Forecast to 2022 | Research Report | Scoop.it
PharmaPoint: Postmenopausal Vaginal Atrophy - Global Drug Forecast and Market Analysis to 2022 is a market research report available at US $9995 for a Single User PDF License from RnR Market Research Reports Library.
Bate Scecile's insight:

The Report “PharmaPoint: Postmenopausal Vaginal Atrophy – Global Drug Forecast and Market Analysis to 2022″ by GlobalData is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “PharmaPoint: Postmenopausal Vaginal Atrophy – Global Drug Forecast and Market Analysis to 2022″ in subject line and your contact details to purchase this report or get your questions answered.

Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past decade, it is expected to undergo a considerable change between 2012 and 2022. This market has historically had a large untreated population due to: low diagnosis rates, safety issues with the existing therapies, and poor patient compliance. Since the mainstay estrogen-based therapies are associated with causing elevated risk for breast cancer, endometrial cancer, and stroke, many women go untreated. However, the launches of three novel drugs with improved safety profiles — Osphena (ospemifene), Vaginorm (prasterone), and BZA/CE (bazedoxifene + conjugated estrogens) — have the potential to tap into the large pool of untreated patients. These non-estrogenic therapies will also shift the PVA treatment paradigm away from systemic estrogen therapies (ETs), such as pills, patches, and gels. Furthermore, awareness campaigns surrounding product launches will likely boost treatment-seeking behavior for the PVA market as a whole. Ultimately these dynamics will be reflected in the moderate growth of the overall PVA market during the forecast period, which will increase from $1.10b in 2012 to $2.1b in 2022 at a Compound Annual Growth Rate (CAGR) of 5.9%.

Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=150341 .

Key Findings

The single most important driver of growth will be the launch of novel, non-estrogen-based drugs that will broaden the eligible population and increase overall treatment rates.The second largest driver will be US healthcare reform, including The Affordable Care Act, which will increase the number of insured women and drive treatment-seeking behavior.The launch of late-stage pipeline products will shift market share away from the vaginal creams and OTC classes towards vaginal tablets and oral therapiesA paradigm shift away from estrogen therapy (ET) has pushed research investment towards selective estrogen receptor modulators (SERMs), tissue-selective estrogen complexes (TSECs), and hormone precursors.

Complete report is available @ http://www.rnrmarketresearch.com/pharmapoint-postmenopausal-vaginal-atrophy-global-drug-forecast-and-market-analysis-to-2022-market-report.html  . Read more on “PharmaPoint: Postmenopausal Vaginal Atrophy – Global Drug Forecast and Market Analysis to 2022” report below.

Scope

Overview of PVA, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.Annualized PVA therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PVA therapeutics market.Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.Analysis of the current and future market competition in the global PVA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.Develop business strategies by understanding the trends shaping and driving the global PVA therapeutics market.Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PVA therapeutics market in future.Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.Track drug sales in the global PVA therapeutics market from 2012-2022.Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

For further information on “PharmaPoint: Postmenopausal Vaginal Atrophy – Global Drug Forecast and Market Analysis to 2022” report OR for any other business research / market intelligence need on the ‘Women's Health therapeutics’ market (http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/womens-health-therapeutics .), contact sales@rnrmarketresearch.com / Call +1 888 391 5441.

 

About Us:

RnRMarketResearch.com is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest.

 

You can also reach us @

http://rnrmarketresearch.blogspot.in/

http://www.rnrmarketresearch.com/blog/

http://www.facebook.com/pages/RnR-Market-Research/413488545356345

https://plus.google.com/u/0/104156468549256253075/

https://twitter.com/#!/RnRMR

http://www.dailymotion.com/rnrmarketresearch

http://www.youtube.com/user/rnrmarketresearch

http://www.slideshare.net/rnrmarketresearch3/

more...
No comment yet.
Scooped by Bate Scecile
Scoop.it!

Mexico Orthopedic Devices Market Forecast to 2020

Mexico Orthopedic Devices Market Forecast to 2020 | Research Report | Scoop.it
Mexico Orthopedic Devices Market Outlook to 2020 - Arthroscopy, Cranio Maxillofacial Fixation (CMF), Hip Reconstruction, Knee Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others is a market research report available at US $9995 for a Single User PDF License from RnR Market Research Reports Library.
Bate Scecile's insight:

The Report “Mexico Orthopedic Devices Market Outlook to 2020 – Arthroscopy, Cranio Maxillofacial Fixation (CMF), Hip Reconstruction, Knee Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others″ by GlobalData is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “Mexico Orthopedic Devices Market Outlook to 2020 – Arthroscopy, Cranio Maxillofacial Fixation (CMF), Hip Reconstruction, Knee Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others″ in subject line and your contact details to purchase this report or get your questions answered.

“Mexico Orthopedic Devices Market Outlook to 2020 Arthroscopy, Cranio Maxillofacial Fixation (CMF), Hip Reconstruction, Knee Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others”, provides key market data on the Mexico Orthopedic Devices market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories Hip Reconstruction, Knee Reconstruction, Shoulder Reconstruction, Small Joint Reconstruction, Orthobiologics, Orthopedic Braces and Supports, Arthroscopy, Cranio Maxillofacial Fixation (CMF), Orthopedic Bone Cement and Casting Materials, Spinal Surgery, Trauma Fixation, Orthopedic Tools and Orthopedic Prosthetics.

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the orthopedic devices market wherever available.

The data in the report is derived from dynamic market forecast models. Researcher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=149072 .

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Complete report is available @ http://www.rnrmarketresearch.com/mexico-orthopedic-devices-market-outlook-to-2020-arthroscopy-cranio-maxillofacial-fixation-cmf-hip-reconstruction-knee-reconstruction-spinal-surgery-orthobiologics-trauma-fixation-and-others-market-report.html .Read more on “Mexico Orthopedic Devices Market Outlook to 2020 – Arthroscopy, Cranio Maxillofacial Fixation (CMF), Hip Reconstruction, Knee Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others” report below.

Scope

Market size and company share data for Orthopedic Devices market categories Hip Reconstruction, Knee Reconstruction, Shoulder Reconstruction, Small Joint Reconstruction, Orthobiologics, Orthopedic Braces and Supports, Arthroscopy, Cranio Maxillofacial Fixation (CMF), Orthopedic Bone Cement and Casting Materials, Spinal Surgery, Trauma Fixation, Orthopedic Tools and Orthopedic Prosthetics.Annualized market revenues (USD million) and volume (units) data for each of the market categories. Data is provided from 2005 to 2012 and forecast to 2020.2012 company shares and distribution shares data for each of the market categories.Global corporate-level profiles of key companies operating within the Mexico Orthopedic Devices market.Key players covered include DePuy Companies, Zimmer Holdings, Inc., Smith & Nephew Plc, Stryker Corporation, Medtronic, Inc., Biomet, Inc., Arthrex, Inc., 3M Health Care Ltd., ConMed Corporation, B. Braun Melsungen AG, Orthofix International N.V., BSN medical GmbH, Wright Medical Group, Inc., Otto Bock HealthCare GmbH, DJO Finance LLC and Ossur hf.

Reasons to buy

Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.Develop market-entry and market expansion strategies.Design competition strategies by identifying who-stands-where in the market.Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.What are the key distribution channels and what’s the most preferred mode of product distribution Identify, understand and capitalize.

For further information on “Mexico Orthopedic Devices Market Outlook to 2020 – Arthroscopy, Cranio Maxillofacial Fixation (CMF), Hip Reconstruction, Knee Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others” report OR for any other business research / market intelligence need on the ‘Orthopedic Device’ market (http://www.rnrmarketresearch.com/reports/life-sciences/medical-devices/orthopedic-device . ), contact sales@rnrmarketresearch.com / Call +1 888 391 5441.

 

About Us:

RnRMarketResearch.com is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest.

 

You can also reach us @

http://rnrmarketresearch.blogspot.in/

http://www.rnrmarketresearch.com/blog/

http://www.facebook.com/pages/RnR-Market-Research/413488545356345

https://plus.google.com/u/0/104156468549256253075/

https://twitter.com/#!/RnRMR

http://www.dailymotion.com/rnrmarketresearch

http://www.youtube.com/user/rnrmarketresearch

http://www.slideshare.net/rnrmarketresearch3/

more...
No comment yet.